Arturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Md Molina sold 10,000 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total value of $570,300.00. Following the completion of the transaction, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,784,360.76. This trade represents a 10.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Arturo Md Molina also recently made the following trade(s):

• On Thursday, March 13th, Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock traded up $1.05 during trading hours on Thursday, reaching $56.39. 321,656 shares of the company were exchanged, compared to its average volume of 888,654. The firm has a market cap of $3.50 billion, a PE ratio of 21.20 and a beta of 2.25. Protagonist Therapeutics, Inc. has a 1 year low of $30.67 and a 1 year high of $60.60. The stock's fifty day moving average is $46.16 and its 200 day moving average is $43.27.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. BMO Capital Markets boosted their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Wedbush reissued an "outperform" rating and set a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $65.44.

Institutional Investors Weigh In On Protagonist Therapeutics

Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can lifted its stake in shares of Protagonist Therapeutics by 4.5% in the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock worth $241,000 after acquiring an additional 270 shares during the period. GF Fund Management CO. LTD. lifted its holdings in shares of Protagonist Therapeutics by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company's stock valued at $74,000 after buying an additional 275 shares during the period. Maryland State Retirement & Pension System raised its position in Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock worth $779,000 after acquiring an additional 278 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after purchasing an additional 300 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock valued at $405,000 after acquiring an additional 330 shares during the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.